ClinicalTrials.gg
WithdrawnNCT05917808Updated Nov 19, 2026

Food Product for Management of Gestational Diabetes

An interventional study of Ready-to-eat wholegrain porridge in Gestational Diabetes, Glucose Tolerance Impaired in Pregnancy and Glucose Tolerance Impaired, sponsored by Stoffwechselzentrum Rhein - Pfalz. Withdrawn at 1 site in Germany. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Stoffwechselzentrum Rhein - Pfalz · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
Recruitment was not possible.
Updated Nov 19, 2026Now WithdrawnEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Diabetes, Gestational with a site in Germany — 6 open to participants now, 6 under way, none of them phase 3. Diabetes, Gestational · Germany.

Started
2023
with 1 other
No phase
6 of 13
2 open now
Registered
8th of 13
by date
Lead sponsor
1 of 13
Stoffwechselzentrum Rhein - Pfalz

Among the 13 studies in Diabetes, Gestational with a site in Germany, this one is one of 2 that started in 2023, is one of 6 with no phase, and was the 8th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

6 of the 13 studies in Diabetes, Gestational with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Diabetes, Gestational with a site in Germany, or all of them as a file.
02

Study summary

The goal of this pilot open pre-post clinical trial is to test effects of a wholegrain product in patients with newly diagnosed gestational diabetes. The main question it aims to answer is:

Does the wholegrain product improve glucose tolerance and insulin sensitivity during a 75 g oral glucose tolerance test (OGTT).

Participants will consume product on two consecutive evenings shortly after the first OGTT and will then perform a second OGTT. Researchers will compare the results of the first and second OGTT to see if glucose tolerance improved after consumption of the test product.

03

Conditions studied

  • Gestational Diabetes
  • Glucose Tolerance Impaired in Pregnancy
  • Glucose Tolerance Impaired
  • Pregnancy Related
  • Insulin Sensitivity/Resistance

Keywords

  • Wholegrain
  • Dietary Intervention
  • Gestational Diabetes
  • Impaired Glucose Tolerance
  • Insulin Sensitivity/Resistance
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pathological fasting glucose or OGTT according to WHO-criteria for the diagnosis of gestational diabetes (see Table 1).
  2. Agree to maintain consistent dietary habits and physical activity levels for the duration of the study.
  3. Willingness to complete questionnaires and follow instructions associated with the study and to perform another OGTT at the clinic in a second visit.
  4. Has given voluntary, written, to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Type 2 diabetes prior to pregnancy
  2. Psychiatric Disease
  3. Acute Infections
  4. Alcohol or drug abuse
  5. Acute diverticulitis
  6. Malignant tumors or hematologic disorders
  7. Heart failure stages III-IV according to (NYHA)
  8. Acute coronary syndrome
  9. Chronic kidney disease > Stage 3 (Kidney Disease Outcomes Quality Initiative - KDOQI)
  10. Celiac disease
  11. Diagnosed Inflammatory bowel diseases (mainly Crohn´s, Ulcerative colitis)
  12. Allergy to ingredients included in the product.
  13. Use of antibiotics within 2 weeks of enrollment
  14. Use of probiotics within 2 weeks of enrollment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Study arm

    Only study arm in the study. Participants consume a ready-to-eat wholegrain porridge on two consecutive evenings and repeat OGTT

    Other: Ready-to-eat wholegrain porridge

Interventions

  • OtherReady-to-eat wholegrain porridge

    A ready-to-eat wholegrain porridget will be consumed shortly after a diagnostic OGTT on two consecutive evenings, the OGTT will then be repeated

06

What researchers measure

Primary outcomes

  1. Change in 2 hour glucose in OGTT

    Change of the 2 hour glucose value in an oral glucose tolerance test

    Time frame: 3-7 working days

Secondary outcomes

  1. Change of the fasting glucose values

    Change in in fasting plasma glucose

    Time frame: 3-7 working days

  2. Change in 1h glucose in OGTT

    Change of the 1h glucose value in an oral glucose tolerance test from the first to the second OGTT

    Time frame: 3-7 working days

  3. Number of values changing from diabetic to non-diabetic values per patient

    Number of values changing from above the diabetic threshold to below diabetic threshold per patient in the cohort according to World Health Organization (WHO) definitions

    Time frame: 3-7 working days

  4. Number of individuals converting from diabetic to non-diabetic OGTT / fasting glucose

    Number of individuals converting from diabetic to non-diabetic OGTT / fasting glucose according to WHO criteria

    Time frame: 3-7 working days

  5. Change in plasma insulin fasting

    Change in plasma insulin fasting between 1st and second OGTT

    Time frame: 3-7 working days

  6. Change in plasma insulin 1 hour during OGTT

    Change in plasma insulin 1 hour during OGTT between 1st and second OGTT

    Time frame: 3-7 working days

  7. Change in plasma insulin 2 hour during OGTT

    Change in plasma insulin 2 hour during OGTT between 1st and second OGTT

    Time frame: 3-7 working days

  8. Change in homeostasis model assessment (HOMA) Index between 1st and second OGTT

    Change in HOMA Index between 1st and second OGTT

    Time frame: 3-7 working days

07

Study locations

1 site
  • Stoffwechselzentrum Rhein-Pfalz
    Mannheim, Baden-Wurttemberg 68163, Germany
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Dec 2023, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2023
First posted
Jun 26, 2023
StartActual
May 29, 2023
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2023
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Withdrawn Recruitment was not possible.
changed Nov 19, 2026
Sites
1 site added, 1 site removed
Show site
  • Stoffwechselzentrum Rhein-Pfalz · Mannheim, Germany
Show 1 removed
  • Stoffwechselzentrum Rhein-Pfalz · Mannheim, Germany
Nov 19, 2026
Enrollment
25 (estimated)→0 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Recruiting→Withdrawn
    Why stopped Recruitment was not possible.
    1 site added, 1 site removed
    Show site
    • Stoffwechselzentrum Rhein-Pfalz · Mannheim, Germany
    Show 1 removed
    • Stoffwechselzentrum Rhein-Pfalz · Mannheim, Germany
    Enrollment 25 (estimated)→0 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05917808
Lead sponsor
Stoffwechselzentrum Rhein - Pfalz
Responsible party
Sponsor
First posted
Jun 26, 2023
Start date
May 29, 2023
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion